Results 141 to 150 of about 15,404 (212)

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. [PDF]

J Diabetes Investig
Ohkuma T, Aotani R, Sakamoto W, Oshiro A, Ago T.   +4 more
europepmc   +1 more source

Dipeptidylpeptidase 4 inhibition attenuates gestational pathologies via immune homeostasis restoration in the pulmonary-uterine axis. [PDF]

Nat Commun
Shi G, Xi S, Lv M, Chen Y, Zhou Y, Wei H, Fu B.   +6 more
europepmc   +1 more source

ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition. [PDF]

Mol Metab
Zheng Z, Pettus JH, Warner A, Jones B, Pugsley M, Stege J, Hirakawa B, Jaiman M, Tolentino J, Lee TL, Kieffer TJ.   +10 more
europepmc   +1 more source

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). [PDF]

PLoS One
Xiong W, Li Y, Huang J, He G, Sun J.
europepmc   +1 more source

Process Validation of Sitagliptin Film Coated Tablets 100 mg

Introduction: Sitagliptin is an antidiabetic medication used to treat type-2 Diabetes Mellitus. As a member of the dipeptidyl peptidase-4 (DPP-4) inhibitor class, Sitagliptin works by inhibiting the enzyme DPP-4, thereby increasing the levels of incretin
Pratibha Thapliyal, Neha Sodiyal, Shivanand Patil
core  

Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial. [PDF]

Diabetologia
Yan H, Liu J, Zhang Z, Chen S, Chang X, Jin H, Li X, Chen Y, Chen Y, Zeng M.   +9 more
europepmc   +1 more source

Improving glucose tolerance in obese rats: the role of Jinlida granules ( ) in gut microbiota modulation. [PDF]

J Tradit Chin Med
Dongqi LI, Tongxing W, Zixuan W, Yihui Y, Jie LI, Jiaojiao GU, Cuiru LI, Aili W, Lingling S, Yongjie M, Zeyu Z, Yunlong H, Huailin G.   +12 more
europepmc   +1 more source

Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial. [PDF]

Diabetes Obes Metab
Lim S, Kim TN, Mok JO, Chung CH, Hwang YC, Cho HC, Won JC, Jeon E, Kang ES, Lee KY, Kim CH, Kwak SH, Park CY, Park KS, Kim SY, Lee JH, Lee SH, Cho DH, Kwon HS, Han KA.   +19 more
europepmc   +1 more source

Potential gonadal-beneficial effect of sitagliptin against paclitaxel-induced testicular dysfunction via mediating PERK/CHOP/NLRP3/Sestrin2 signaling pathway. [PDF]

Sci Rep
El-Beheiry KM, El-Shitany NA, El-Sayad ME, Elsisi AE.   +3 more
europepmc   +1 more source

Prevalence and treatment of mitochondrial diabetes in Southwest Finland. [PDF]

J Diabetes Metab Disord
Rindell N, Immonen H, Martikainen MH.
europepmc   +1 more source